Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

FDA approves Miltenyi Biotec's CliniMACS CD34 Reagent System for prevention of GVHD

Miltenyi Biotec announced today that the U.S. Food and Drug Administration has approved the company's CliniMACS CD34 Reagent System as a Humanitarian Use Device for the prevention of graft-versus-host disease in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from a matched related donor.

24 Jan 2014

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

Use of a twice-daily pill could turn a deadly blood cancer into a highly treatable disease, according to scientists at Weill Cornell Medical College who led a multinational research team.

24 Jan 2014

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposi's sarcoma.

23 Jan 2014

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received notice from the U.S. Food & Drug Administration confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for Acute Myeloid Leukemia.

23 Jan 2014

NCCC physicians use new gene sequencing equipment for testing abnormal DNA in cancerous tumor cells

Clinical laboratory experts and physicians at Dartmouth-Hitchcock Norris Cotton Cancer Center (NCCC) achieved 100 percent accuracy in testing for abnormal DNA in cancerous tumor cells with its new gene sequencing equipment and panels.

23 Jan 2014

New oral drug appears to offer hope for fighting indolent non-Hodgkin lymphoma

Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing repeatedly and the disease becoming increasingly resistant to therapy over time.

22 Jan 2014

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.

22 Jan 2014

Cost of care, diabetes are top Latino health concerns

Worries about being able to afford care and about diabetes were among the biggest health concerns among Latinos -- whether they were born in the U.S. or immigrated here, according to the latest survey by NPR, the Robert Wood Johnson Foundation and the Harvard School of Public Health. Other media outlets explore the limited options of those living in this country illegally.

21 Jan 2014

Mutation in bone cells may cause acute myeloid leukemia: Study

Acute myeloid leukemia is a blood cancer, but for many patients the cancer may originate from an unusual source: a mutation in their bone cells.

21 Jan 2014

Damon Runyon Cancer Research Foundation awards $2.25M to six innovative young scientists

The Damon Runyon Cancer Research Foundation announced that six scientists with novel approaches to fighting cancer have been named 2014 recipients of the Damon Runyon-Rachleff Innovation Award. The grant of $450,000 over three years is awarded each year to early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer.

21 Jan 2014

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a pivotal, CE Mark registration trial for BL-5010P, for the non-surgical removal of benign skin lesions.

21 Jan 2014

First Edition: January 21, 2014

Today's headlines include news on the health law's implementation at both the federal and state levels.

21 Jan 2014

Scientists discover novel mechanism that influences GAS virulence at early steps of necrotizing fasciitis

How does Streptococcus pyogenes, or Group A streptococcus (GAS) — a bacterial pathogen that can colonize humans without causing symptoms or can lead to mild infections — also cause life-threatening diseases such as necrotizing fasciitis (commonly known as flesh-eating disease) and streptococcal toxic shock syndrome?

21 Jan 2014

Viewpoints: Is overhaul really a 'war' on the young?; war on poverty requires spending; maternity leave in America

A long-shot lawsuit that could have damaged the effectiveness of health care reform got a well-deserved brushoff from a federal district judge on Wednesday.

20 Jan 2014

Research may lead to potential treatment for deadly bacterial infections

Collaboration between the National University of Singapore (NUS) and The Hebrew University of Jerusalem (HUJ) on inflammation research may lead to a potential treatment for deadly bacterial infections

20 Jan 2014

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals, Inc. today announced the commercial availability of Iclusig (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.

18 Jan 2014

Three new spin-offs emerged from Helmholtz Zentrum München

Three new spin-offs emerged from Helmholtz Zentrum München (HMGU) in 2013: SurgVision, Trianta Immunotherapies and Dosimetrics. Thanks to successful innovation management, the Center has transformed excellent research findings into practical applications and given new impulses to the areas of clinical imaging, immunotherapy and radiation dosimetry.

17 Jan 2014

Research opens way to possible new treatments for bacterial infections

How does Streptococcus pyogenes, or Group A streptococcus (GAS) - a bacterial pathogen that can colonize humans without causing symptoms or can lead to mild infections - also cause life-threatening diseases such as necrotizing fasciitis (commonly known as flesh-eating disease) and streptococcal toxic shock syndrome?

17 Jan 2014

Biothera enhances innate immune responses to Imprime PGG drug candidate

Biothera has enhanced innate immune responses to its cancer immunotherapy drug candidate Imprime PGG in subjects regardless of biomarker status, demonstrating the opportunity to treat a larger patient population. The in vitro research will be presented today at the Cambridge Healthtech Institute's Antibody-Drug Conjugates/Engineering Targeted Therapeutics conference in Palm Springs, CA.

16 Jan 2014

Scientists discover genetic signature mechanism in immune system as driving force for childhood leukaemia

Scientists have discovered a genetic signature that implicates a key mechanism in the immune system as a driving force for a type of childhood leukaemia.

13 Jan 2014

Leukemia News and Research

Further Reading

FDA approves Miltenyi Biotec's CliniMACS CD34 Reagent System for prevention of GVHD

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

NCCC physicians use new gene sequencing equipment for testing abnormal DNA in cancerous tumor cells

New oral drug appears to offer hope for fighting indolent non-Hodgkin lymphoma

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

Cost of care, diabetes are top Latino health concerns

Mutation in bone cells may cause acute myeloid leukemia: Study

Damon Runyon Cancer Research Foundation awards $2.25M to six innovative young scientists

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

First Edition: January 21, 2014

Scientists discover novel mechanism that influences GAS virulence at early steps of necrotizing fasciitis

Viewpoints: Is overhaul really a 'war' on the young?; war on poverty requires spending; maternity leave in America

Research may lead to potential treatment for deadly bacterial infections

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

Three new spin-offs emerged from Helmholtz Zentrum München

Research opens way to possible new treatments for bacterial infections

Biothera enhances innate immune responses to Imprime PGG drug candidate

Scientists discover genetic signature mechanism in immune system as driving force for childhood leukaemia

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News